Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 18;65(6):e00084-21.
doi: 10.1128/AAC.00084-21. Print 2021 May 18.

In Vitro Susceptibility of Multidrug-Resistant Pseudomonas aeruginosa following Treatment-Emergent Resistance to Ceftolozane-Tazobactam

Abigail M Rubio  1 , Ellen G Kline  1 , Chelsea E Jones  1 , Liang Chen  2   3 , Barry N Kreiswirth  2 , M Hong Nguyen  1   4   5 , Cornelius J Clancy  1   4   6 , Vaughn S Cooper  7   8 , Ghady Haidar  1 , Daria Van Tyne  1 , Ryan K Shields  9   4   5
Affiliations

In Vitro Susceptibility of Multidrug-Resistant Pseudomonas aeruginosa following Treatment-Emergent Resistance to Ceftolozane-Tazobactam

Abigail M Rubio et al. Antimicrob Agents Chemother. .

Abstract

We compared the in vitro susceptibility of multidrug-resistant Pseudomonas aeruginosa isolates collected before and after treatment-emergent resistance to ceftolozane-tazobactam. Median baseline and postexposure ceftolozane-tazobactam MICs were 2 and 64 μg/ml, respectively. Whole-genome sequencing identified treatment-emergent mutations in ampC among 79% (11/14) of paired isolates. AmpC mutations were associated with cross-resistance to ceftazidime-avibactam but increased susceptibility to piperacillin-tazobactam and imipenem. A total of 81% (12/16) of ceftolozane-tazobactam-resistant isolates with ampC mutations were susceptible to imipenem-relebactam.

Keywords: Pseudomonas aeruginosa; antibiotic resistance; ceftolozane-tazobactam; imipenem-relebactam.

PubMed Disclaimer

References

    1. CDC. 2019. Antibiotic resistance threats in the United States, 2019. CDC, Atlanta, GA.
    1. Pogue JM, Kaye KS, Veve MP, Patel TS, Gerlach AT, Davis SL, Puzniak LA, File TM, Olson S, Dhar S, Bonomo RA, Perez F. 2020. Ceftolozane/tazobactam vs polymyxin or aminoglycoside-based regimens for the treatment of drug-resistant Pseudomonas aeruginosa. Clin Infect Dis 71:304–310. doi:10.1093/cid/ciz816. - DOI - PubMed
    1. Buehrle DJ, Shields RK, Chen L, Hao B, Press EG, Alkrouk A, Potoski BA, Kreiswirth BN, Clancy CJ, Nguyen MH. 2016. Evaluation of the in vitro activity of ceftazidime-avibactam and ceftolozane-tazobactam against meropenem-resistant Pseudomonas aeruginosa isolates. Antimicrob Agents Chemother 60:3227–3231. doi:10.1128/AAC.02969-15. - DOI - PMC - PubMed
    1. Haidar G, Philips NJ, Shields RK, Snyder D, Cheng S, Potoski BA, Doi Y, Hao B, Press EG, Cooper VS, Clancy CJ, Nguyen MH. 2017. Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: clinical effectiveness and evolution of resistance. Clin Infect Dis 65:110–120. doi:10.1093/cid/cix182. - DOI - PMC - PubMed
    1. Shields RK, Haidar G, Potoski BA, Doi Y, Marini RV, Nguyen MH, Clancy CJ. 2018. Ceftolozane-tazobactam against multidrug-resistant Pseudomonas aeruginosa infections: clinical efficacy and emergent resistance, abstr 2438. IDWeek 2018, San Francisco, CA. doi:10.1093/ofid/ofy210.2091. - DOI

Publication types

MeSH terms